Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

Virax Biolabs Group Limited has announced a definitive agreement for the immediate exercise of certain outstanding preferred investment options, which is expected to generate approximately $3.3 million in gross proceeds. The transaction, which involves the exercise of options for 548,000 ordinary shares, was disclosed on July 9, 2026. The original exercise price of these options, initially set at $10.00 per share, has been reduced to $6.00 per share, facilitating the fundraising effort.

Virax Biolabs, a biotechnology company listed on Nasdaq under the ticker VRAX, specializes in immune response detection and T cell immune profiling. The company is focused on developing in vitro diagnostic technologies aimed at addressing viral and immune-mediated diseases, with particular attention to post-acute infection syndromes such as Long COVID. The funds raised from this transaction are intended to support the company's working capital needs and general corporate purposes, thereby bolstering its ongoing research and development initiatives.

The role of H.C. Wainwright & Co. as the exclusive placement agent underscores the strategic importance of this fundraising effort. The new investment options include Series A and Series B Preferred Investment Options, which will allow for the purchase of an aggregate of 1,096,000 ordinary shares at the reduced exercise price. The Series A options will be exercisable following shareholder approval for an increase in authorized ordinary shares, while the Series B options will have a shorter exercise period of eighteen months post-approval.

This fundraising initiative comes at a time when the biotechnology sector is experiencing significant interest from investors, particularly in companies focused on innovative diagnostic solutions and treatments for complex health issues. The reduction in the exercise price is indicative of market conditions that favor capital raising efforts, as companies seek to attract investment amid evolving healthcare demands.

Looking ahead, the successful closing of this offering, anticipated around July 10, 2026, could enhance Virax Biolabs' capacity to advance its product pipeline and strengthen its market position. As the biotechnology sector continues to evolve, companies like Virax that focus on addressing unmet medical needs may find increased opportunities for growth and collaboration, particularly in the wake of the ongoing global health challenges.